MacroGenics share price logo

MacroGenics

NASDAQ: MGNX

$2.33

as on

MacroGenics Stock Performance

as on November 10, 2026 at 7:59 am IST

  • Day's High

    $2.33
    $2.49

    6.87%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.32
    $5.08
    downward going graph

    43.35%

    Downside

    118.03%

    Upside

    downward going graph

MacroGenics share price movements today

Previous Close
$2.33
Open
$2.36
Volume
1.5M
Market Cap
$148.4M
Day's Low - High
$2.33 - $2.49
52 Week Low - High
$1.32 - $5.08

MacroGenics Historical Returns

1 Month Return
-37.7 %
3 Month Return
-42.33 %
1 Year Return
+ 70.07 %
3 Year Return
-64.43 %
5 Year Return
-89.05 %

MacroGenics Stock Fundamentals & Key Indicators

Check MacroGenics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$148.4M

EPS (TTM)

-0.22

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.70%

PE Ratio (TTM)

-10.59

Industry PE ratio

-3.15

PEG Ratio

0.09

EBITDA

-81.7M

Revenue (TTM)

167.7M

Profit Margin

50.44%

Return On Equity TTM

-31.27%

MacroGenics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of MacroGenics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
MacroGenics image
MacroGenics
Buy$148.4M-89.05%-10.5950.44%0.00%
Moderna image
Moderna
Neutral$101.5B7.32%-35.9528.00%0.00%
BeOne Medicines image
BeOne Medicines
StrongBuy$46.5BNA66.6588.39%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$138.7B186.30%34.9485.57%0.00%
Regeneron image
Regeneron
Buy$93.5B46.74%19.2685.77%0.41%

Stock Returns calculator for MacroGenics Stock including INR - Dollar returns

The MacroGenics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

MacroGenics investment value today

Current value as on today

₹1,80,082

Returns

₹80,082

(+80.08%)

Returns from MacroGenics Stock

₹70,073 (+70.07%)

Dollar Impact

₹10,009 (+10.01%)

Analyst Recommendation on MacroGenics Stock

Based on 4 analysts

BUY

50.00%

Buy

50.00%

Hold

0.00%

Sell

Based on 4 analysts, 50% of analysts recommend a 'BUY' rating for MacroGenics. Average target price of $8

MacroGenics Share Price Target

Get share price movements and forecasts by analysts on MacroGenics.

What analysts predicted

70.88%UPSIDE

Target Price

$8

Current Price

$2.33

Analyzed by

4 Analysts

High

$11

Target

$8.00

Low

$4

MacroGenics target price $8, a slight upside of 70.88% compared to current price of $2.33. According to 4 analysts rating.

Indian Investors' Interest in MacroGenics Stock

Search interest for MacroGenics Stock has decreased by -60% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-60% versus previous 30 day period

MacroGenics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
9
10
110
17
13
22
72
41
20
32
Gross Profit
6
7
68
12
6
11
59
29
9
-13
Operating Income
-53
-58
54
-52
-42
-36
18
-12
-33
-13
EBITDA
-49
-53
58
-12
-39
-33
21
-8
-30
-64
Interest Expense
1
0
-
-
0
0
3
4
4
4
Depreciation
1
1
1
2
1
1
1
1
1
0
Income Before Tax
-52
-55
56
-14
-41
-36
16
-14
-36
-69
Income Tax Expense
-
-
-
0
-
0
-
0
-
-89
Net Income
-52
-55
56
-15
-41
-36
16
-14
-36
19
Net Profit Margin
76.76%
73.85%
61.69%
69.04%
45.64%
51.38%
81.63%
71.33%
46.01%
-42.19%

MacroGenics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
155
60
62
97
75
150
57
148
149
Gross Profit
155
60
62
97
72
142
48
136
106
Operating Income
-22
-171
-177
-131
-202
-121
-168
-110
-72
EBITDA
-14
-162
-164
-119
-190
-107
2
-57
-59
Interest Expense
-
-
-
-
-
-
1
1
8
Depreciation
7
9
12
11
11
11
9
7
7
Income Before Tax
-19
-171
-151
-129
-202
-119
-9
-66
-75
Income Tax Expense
-
0
-
-
-
-
-
0
0
Net Income
-19
-171
-151
-129
-202
-119
-9
-66
-74
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
96.50%
95.08%
85.62%
91.71%
71.12%

MacroGenics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-52
-55
56
-15
-41
-36
16
-14
-36
19
Operating Cash Flow
-45
-44
60
-38
-46
-46
-30
43
-35
-40
Investing Cash Flow
24
47
35
41
9
-37
-20
-65
45
27
Financing Cash Flow
0
0
0
0
0
69
-
0
0
60
Change in Cash
-20
3
95
3
-37
-14
-50
-22
9
47

MacroGenics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-19
-171
-151
-129
-202
-119
-9
-66
-74
Operating Cash Flow
14
-153
-134
-111
-143
-86
-78
-68
-81
Investing Cash Flow
77
56
-79
-7
-36
70
-80
149
-114
Financing Cash Flow
35
104
119
174
122
1
150
0
69
Change in Cash
127
8
-93
54
-57
-14
-7
81
-125

Global Institutional Holdings in MacroGenics

Check out the Institutions with significant holdings in MacroGenics.

Funds
Holdings
BlackRock, Inc.
7.35%
Vanguard
5.20%
VANGUARD INDEX FUNDS
4.04%
iShares
3.89%
Peter Kolchinsky
2.93%
See all

Insights on MacroGenics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 20.77M → 32.83M (in $), with an average increase of 36.7% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -36.77M → 19.51M (in $), with an average increase of 288.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 265.7% return, outperforming this stock by 330.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 935.8% return, outperforming this stock by 865.7%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, MGNX stock has moved down by -37.7%

About MacroGenics

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
OrganisationMacroGenics
Headquarters9704 Medical Center Drive, Rockville, MD, 20850, US
IndustryBiotechnology
CEOEric Risser

Key Management of MacroGenics

Name

Title

Mr. Eric Blasius Risser

CEO, President & Director

Mr. Harish Krishnaswamy

Senior Vice President of Business Development & Portfolio Planning

Dr. Frank George Perabo FEBU, M.D., Ph.D.

Vice President & Interim Head of Clinical Development

Ms. Beth Smith

VP, Controller & Treasurer

Mr. James Karrels

Senior VP & CFO

Dr. Ezio Bonvini M.D.

Senior VP of Research & Chief Scientific Officer

Dr. Araba Lamouse-Smith Ph.D.

Vice President of Technical Operations

Mr. Jeffrey Stuart Peters J.D.

Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer

Mr. Steve Harig

Senior Vice President of Human Resources

FAQs

What is MacroGenics share price today?

MacroGenics share price today is $2.33 as on at the close of the market. MacroGenics share today touched a day high of $2.49 and a low of $2.33.

What is the 52 week high and 52 week low for MacroGenics share?

MacroGenics share touched a 52 week high of $5.08 on and a 52 week low of $1.32 on . MacroGenics stock price today i.e. is closed at $2.33,which is 54.13% down from its 52 week high and 76.52% up from its 52 week low.

What is MacroGenics's market capitalisation today?

MacroGenics market capitalisation is $0.00T as on .

How to invest in MacroGenics Stock (MGNX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for MacroGenics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy MacroGenics Stock (MGNX) from India?

Indian investors can start investing in MacroGenics (MGNX) shares with as little as ₹93.92749786376953 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹939.27 in MacroGenics stock (as per the Rupee-Dollar exchange rate as on ). Based on MacroGenics share’s latest price of $2.33 as on November 10, 2026 at 2:29 am IST, you will get 4.2918 shares of MacroGenics. Learn more about fractional shares .

What are the returns that MacroGenics has given to Indian investors in the last 5 years?

MacroGenics stock has given -89.05% share price returns and 26.61% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?